
Novo Nordisk A/S says FDA extends denecimig review over facility remediation
The company says the agency has set no new action date, while its U.S. launch target remains conditional on approval.

The GL1 hole lies about 100 metres southeast of earlier drilling; assays from ten more holes in the completed program remain pending.

The company says the agency has set no new action date, while its U.S. launch target remains conditional on approval.

Bitdeer's Oct. 3 update lists zero pure bitcoin holdings as of Oct. 2 but gives no sale price, proceeds or mining costs.
The Nevada lithium study assumes US$24,000 per tonne of lithium carbonate and US$2.77 billion in first-phase capital.
Rebisufligene etisparvovec won U.S. approval on Sept. 17; Ultragenyx gave no date for a European decision.

The Oct. 1 close follows a 25 million share proposal, but the completion notices give no final ownership percentage or cash proceeds to the parent.

TVA's Clinch River permit took effect Sept. 28; GE Vernova's Sept. 29 release states no equipment price or delivery date.

One petition is active and the other pending review; both would let Florida medical operators sell to adults if voters approve.

TransAlta sought US$19.9M for the first 90 days of a federal emergency order; FERC rejected the proposed allocation of those costs.
State approvals cleared the Oct. 1 transfer of certain Ohio operations; AYR disclosed no cash proceeds or debt relief figure.
About 40 gas units are set for staged deployment from late 2026, with revenue expected to begin in the first quarter of 2027.
Gross margin reached about 48 per cent in the June half, while WISeQey shares are due to trade as WQEY on Oct. 5 after an ADS conversion.
The ARTG's Sept. 15 entry names Jupiter Research as manufacturer; Curaleaf also reports a Sept. 17 New Zealand WAND notification.
Facility A begins at 7.25 per cent and Facility B stays at 9.95 per cent under a Sept. 28 agreement backed by subsidiary assets.
A 1.21-metre section graded 30.46% antimony, while the 2025 feasibility study assigns the metal no revenue.
Shareholders approved the Armada combination Sept. 30, while Evernorth expects roughly US$300M of gross cash before expenses.
Gold, silver, uranium, lithium, copper and rare earths: the producers, the developers and the projects behind them.
View all
Argentina's incentive regime offers 30 years of stability as Glencore advances Alumbrera's first-production target to the second half of 2027.
Medical and pharmaceutical developments, psychedelics, and the research and safety questions around them.
View all
SITC presentations will follow a three-year EVX-01 clinical update on Oct. 24; the 75% response rate was first reported in 2025.
Technology, computing, crypto and cannabis, and the listed companies moving in them.
View all
The TSX Venture company has issued US$10.5 million of secured convertible notes and will seek shareholder approval for preferred shares on Oct. 14.
We Energies says Oracle would take on part of its required nuclear power purchase; Oracle says the subscription needs Wisconsin commission approval.
Uranium, lithium, oil and gas, hydrogen and the grid: the fuels and the companies behind them.
View all
Marimaca's Oct. 1 update names no supplier, contracted volume or energization date for its preliminary five-year power framework.

Commerce's Bureau of Industry and Security authorised sales under specified terms; the company did not name an export buyer or shipment date.

The proposed transfer covers seven reactors and related liabilities, but the Sept. 30 notice gives no price or signing date.
Licensed producers, retail, policy, and the psychedelics companies moving through the clinic.
View all
Colorado completed its review on Sept. 29; permit issuance requires verified warranties, and DOE mine-plan approval remains pending.

The uncontrolled Canadian trial enrolled 11 patients; seven were evaluable for pain, and validated data analysis remains underway.

Lifted Made closed the Kenosha building sale Sept. 29 and used US$841,110 to repay all its outstanding bank debt.

A Sept. 29 stay in DEA hearing docket 26-96 sets Oct. 13 for a response to a motion seeking to add the GAO report to the record.